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What's already known about this topic?  
The detrimental impact of pemphigus on health-related quality of life has been reported in the 
literature. No studies have used the EQ-5D questionnaire in pemphigus patients, so far. 
 
What does this study add? 
This is the first study employing the EQ-5D questionnaire in pemphigus. The EQ-5D is a valid 
instrument for the evaluation of health-related quality of life in pemphigus vulgaris and 
foliaceus. Pain intensity, mucocutaneous involvement and comorbidities are important 
predictors of quality of life. The EQ-5D might help to better understand the health loss from 
pemphigus. 
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Abstract 
 
Background: No studies have employed the EuroQoL (EQ-5D) questionnaire to assess health-
related quality of life (HRQoL) in pemphigus patients, to date. 
Objectives: To evaluate HRQoL of pemphigus patients by the EQ-5D and to analyse the 
convergent and known-groups validity of the EQ-5D in this patient population.  
Methods: Between 2014 and 2017, a multicentre cross-sectional study was carried out. 
Outcome measures included the five-level EQ-5D (EQ-5D-5L), Dermatology Life Quality 
Index (DLQI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and an average 
pain intensity visual analogue scale (VAS) for the past three months.  
Results: 109 consecutive patients with pemphigus participated in the study (mean age 57 years; 
women 64%). Among the EQ-5D dimensions, the most problems were reported regarding 
pain/discomfort (50%), mobility (43%) and anxiety/depression (43%). No significant 
difference was found in mean EQ-5D index scores between patients with pemphigus vulgaris 
and foliaceus (0.81 vs. 0.86; p=0.142). Mean EQ-5D index scores of patients with limited, 
moderate, significant and extreme pemphigus were 0.88, 0.82, 0.72 and 0.67, respectively 
(p=0.001). The number of comorbidities was associated with greater impairment in EQ-5D 
index scores (p<0.001). DLQI (rs=-0.62; p<0.001) and the average pain intensity VAS (rs=-
0.59; p<0.001) more strongly correlated with the EQ-5D index scores than ABSIS (rs=-0.40; 
p<0.001).  
Conclusions: This is the first study employing the EQ-5D questionnaire in pemphigus. The 
EQ-5D is a valid measure of HRQoL in pemphigus patients that can be useful both in clinical 
practice and in economic evaluations to assess the health gains associated with new effective 
treatments. 
 
  
4 
 
Keywords: pemphigus vulgaris, pemphigus foliaceus, autoimmune blistering diseases, 
health-related quality of life, utility, EQ-5D, DLQI, ABSIS 
 
 
 
 
 
 
  
  
5 
 
Introduction 
Pemphigus is a group of mucocutaneous autoimmune blistering diseases caused by 
autoantibodies against cell-surface proteins on keratinocytes. The major subtypes include 
pemphigus vulgaris (PV), pemphigus foliaceus (PF) and a less frequent form, IgA pemphigus.1 
PV accounts for approximately 70-90% of all cases with an annual incidence rate of 0.76 to 32 
per million.2,3 Usual age of onset is between 50-60 years, and female-to-male ratio is ranging 
between 1.1 and 2.3 in Europe and Asia, but much higher (4.0 and 4.1) in Africa.4 The clinical 
manifestation of PV is characterised by the formation of blisters that easily rupture leaving 
erosions on the skin and/or mucosa.5 Although it may develop in any localisation, the most 
commonly affected sites are the scalp, face, neck, trunk, groin and the oropharyngeal mucosa.6 
In contrast, patients with PF rarely develop mucosal involvement. Lesions in pemphigus may 
be highly painful, show no tendency to heal spontaneously, and are susceptible to 
superinfection. According to current guidelines, systemic corticosteroid therapy is regarded as 
first-line treatment in pemphigus.7-9 An important milestone of 2017 was rituximab combined 
with short-term prednisone being granted approval as a first-line treatment for PV by the US 
Food and Drug Administration (FDA).10 
 
The detrimental impact of pemphigus and treatment-related side effects on health-related 
quality of life (HRQoL) have been reported in the literature.11-13 However, so far, no health 
utility values have been measured in pemphigus patients. Health utilities are preference-based 
HRQoL values that are needed to calculate quality-adjusted life years (QALYs) in cost-
effectiveness analyses of treatments. Of the commonly used generic instruments, EuroQoL 5-
dimension (EQ-5D) questionnaire is advocated as a validated, self-reporting tool to derive 
utility scores.14 Given the general character of the EQ-5D, it allows comparisons across a broad 
range of disease areas and with counterparts in the general public. The EQ-5D has demonstrated 
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a good validity and responsiveness in a number of dermatological conditions, including 
psoriasis, atopic dermatitis, hidradenitis suppurativa and acne.15-17 Yet no studies have 
employed the EQ-5D questionnaire in pemphigus patients, to date. Therefore, the objectives of 
our study were i) to evaluate HRQoL in pemphigus patients using the EQ-5D; ii) to compare 
the burden of pemphigus vulgaris and foliaceus to that of psoriasis measured by the EQ-5D; 
and iii) to analyse the convergent and known-groups validity of the EQ-5D in pemphigus 
patients.  
 
Methods 
Study design and patients 
Between December 2014 and June 2017, a cross-sectional study was conducted in four 
academic dermatology departments in Hungary. Consecutive patients over 18 years of age 
diagnosed with any form of pemphigus were enrolled after an informed consent form was read 
and signed. Permission for conducting the study was granted by the National Scientific and 
Ethical Committee (reference No. ETT-TUKEB 27416-3/2016/EKU). The questionnaire 
consisted of two sections. The patients’ section included questions regarding demographic data, 
comorbidities and HRQoL. Physicians’ section contained questions referring to disease 
characteristics, medical history, disease severity and treatments applied. 
  
Outcome measures 
EQ-5D-5L 
The validated Hungarian version of the EQ-5D-5L questionnaire was used in the study. EQ-
5D-5L is a generic, self-reported, preference-based measure of health that consists of a five-
item descriptive system and a visual analogue scale (EQ VAS).18 The five dimensions of health 
ask about mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each 
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dimension has five response levels (1-no problems, 2-slight problems, 3-moderate problems, 4-
severe problems, 5-extreme problems/unable) and the different combinations of answers define 
55=3125 distinct health states.19,20 Each health state can be assigned a utility value (i.e. EQ-5D-
5L index score) obtained from population studies reflecting the societal values. In absence of a 
national value set in Hungary, the 5L value set for England developed by Devlin et al. was 
applied in this study to derive utility values, whereby utilities range between -0.285 and 1.21 EQ 
VAS is a 20-cm-long, vertical visual analogue scale with endpoints of ‘0’ (‘The worst health 
you can imagine’) and ‘100’ (‘The best health you can imagine’). It provides a self-rating of 
patients’ current health status.  
 
Dermatology Life Quality Index (DLQI) 
The validated Hungarian version of the DLQI was administered to patients.22 We have decided 
to use the DLQI, as it is the most frequently employed tool for measuring dermatology-specific 
HRQoL in pemphigus patients.23,24 It has been successfully used in cross-sectional and case-
control studies as well as in the Ritux 3 clinical trial for first-line rituximab in pemphigus.25-30 
The ten-item questionnaire covers the commonly mentioned aspects of life affected by skin 
disease: symptoms and feelings, daily activities, leisure, school and work, personal 
relationships, and treatments. The DLQI has a possible scoring range of 0–30, with ‘30’ 
corresponding to the worst, and ‘0’ corresponding to the best score. 
 
Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) 
ABSIS is validated disease severity scale for pemphigus.31-33 The ABSIS score ranges between 
0 and 206, with 150 points for skin involvement, 11 points for oral involvement, and 45 points 
for subjective discomfort. Since HRQoL is based on subjective perceptions of the patients, we 
have considered the ABSIS with its subjective component to be particularly useful to test the 
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convergent validity of the EQ-5D. Of note, as there is no relevant difference in diet between 
Western Europe and Hungary with respect to the food item list of ABSIS, the foods are kept 
exactly the same as in the English-language version. Subgroups of disease activity are defined 
based on the cut-off values developed by Boulard et al.: limited (ABSIS 0-3), moderate (ABSIS 
4-16), significant (ABSIS 17-52) and extensive (ABSIS 53-206) pemphigus.34  
 
Global and pain assessments 
Furthermore, to assess disease severity the Physicians’ Global Assessment (PGA) VAS and 
Patient's Global Assessment (PtGA) VAS were administered, both providing a range of scores 
from 0-100, where 0 indicated ‘not severe at all’ and 100 represented ‘very severe’. The average 
and worst pemphigus-related pain intensities experienced by the patients in the past three 
months were recorded on a 10-cm-long, horizontal VAS with the endpoints of ‘no pain at all’ 
(=0) and ‘pain as bad as it could be’ (=100).35  
 
Statistical analyses 
Demographic and clinical characteristics were reported as proportions for categorical variables 
and means and standard deviations (SD) as well as medians and interquartile ranges (IQR) for 
continuous variables.  
Non-parametric Mann Whitney U and Kruskal-Wallis H tests were used to compare patient- 
and physician-based outcome scores in subgroups of patients. Analysis of the relationship 
between continuous variables was accomplished by calculating Spearman’s correlation 
coefficients (very weak correlation: rs<0.2; weak correlation 0.20≤rs<0.4; moderate correlation 
0.4≤rs<0.6; strong correlation 0.6≤rs≤1). EQ-5D-5L and EQ VAS results were compared with 
responses from a group of Hungarian patients with psoriasis obtained in a previous study by 
our research group (N=238, mean age 47.4±15.2 years, rate of moderate-to-severe psoriasis 
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81%).36 For all the statistical tests a two-sided p-value of <0.05 was considered statistically 
significant. All statistical analyses were performed using SPSS 22.0 (Armonk, NY: IBM Corp. 
2013). 
 
Results 
Patient characteristics 
In total, 109 pemphigus patients participated in the study. Mean age was 57.2±14.8 (range 19-
93) years, and 64.2% were males (Table 1). Nearly 80% completed at least a high school 
education. The proportion of patients over the retirement age was 30.3%. Mean disease duration 
was 3.8 years. The most frequently represented subtype was PV (n=81), whereas 27 patients 
were presented with PF, and one patient had IgA pemphigus. The majority of patients had 
limited (45.9%) or mild (30.3%) pemphigus at the time of the survey. The most commonly used 
treatments were systemic corticosteroid therapy (70.6%), azathioprine (42.2%) and 
cyclophosphamide (10.1%) (combinations occurred). 
 
Disease severity and HRQoL scores 
Overall, 50%, 43%, 43%, 42% and 19% of the pemphigus patients reported problems in 
pain/discomfort, mobility, anxiety/depression, usual activities and self-care dimensions of the 
EQ-5D-5L descriptive system, respectively. Sixty different EQ-5D-5L health states occurred 
among the patients. The best health state (11111) was indicated by 31 patients (28.7%); thus, a 
substantial ceiling effect of the EQ-5D-5L descriptive system was detected. No negative EQ-
5D-5L index scores were observed (i.e. health states being worse than dead). Mean EQ-5D-5L 
index and EQ VAS scores were 0.82±0.21 and 68.0±22.3, respectively (Table 2). Mean DLQI 
score was 5.4±6.9, with the most problems reported regarding sore, itchy or painful skin (48%), 
embarrassment (48%) and clothing (36%). Overall, 40 patients (37.4%) had a DLQI total score 
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of zero. The mean ABSIS score for the sample was 11.7±17.3. Mean scores on PGA VAS were 
significantly lower than PtGA VAS (26.9±27.4 vs. 46.0±35.5; p<0.001). Mean worst pain 
intensity scores on VAS were significantly higher compared with average pain intensity scores 
(33.6±30.6 vs. 21.4±37.6; p<0.001). 
 
Comparison of PV and PF patients 
ABSIS scores showed a trend toward higher severity score in PV compared with PF (Table 2). 
Patients affected by PV tended to have worse scores both in EQ-5D-5L index and EQ VAS. 
However, PF patients experienced greater HRQoL impairment as measured with the DLQI. 
Patients with PV indicated significantly higher scores on worst pain intensity VAS as compared 
with PF (p<0.05). 
 
EQ-5D-5L and EQ VAS results of patients with pemphigus vulgaris, pemphigus foliaceus 
in comparison with a previous study in psoriasis 
A greater proportion of PV patients indicated problems in all five dimensions of the EQ-5D-5L 
than PF patients, especially concerning usual activities and mobility (Fig. 1). In all dimensions, 
PV patients reported approximately equal or more problems than psoriasis patients, while PF 
patients experienced nearly equal or less problems than patients with psoriasis. When PV and 
psoriasis patients were compared, the most pronounced difference was observed in usual 
activities (51% vs. 32% reported at least slight problems, and 11% vs. 3% reported severe or 
extreme problems). Psoriasis patients’ EQ-5D-5L index (0.84) and EQ VAS scores (72.5) were 
very similar to those of patients with PV and PF (p>0.05). 
 
Convergent validity 
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EQ-5D-5L index scores demonstrated a strong correlation with DLQI and EQ VAS scores, a 
moderate-to-strong correlation with average pain intensity VAS and a moderate correlation 
with ABSIS, PGA VAS, PtGA VAS and worst pain intensity VAS scores (p<0.001) (Table 3). 
In contrast, EQ VAS moderately correlated with the DLQI and the scores on pain intensity 
scales (p<0.001). There was a weak, insignificant correlation between EQ VAS and ABSIS 
scores. PGA VAS highly correlated with both the DLQI and ABSIS (p<0.001). A weak 
negative correlation was found between age and both the EQ-5D-5L index scores (p<0.01) and 
the EQ VAS (p<0.05). 
 
Known-groups validity 
There was no statistically significant difference in EQ-5D-5L index scores between females 
and males (Table 4). Mean EQ-5D-5L index scores of patients with limited, moderate, severe 
and extreme disease were 0.88±0.18, 0.82±0.21, 0.72±0.23 and 0.67±0.24, respectively 
(p=0.001). Similarly, it was able to detect significant difference across PV patients with no 
lesions, mucocutaneous lesions, skin involvement only and mucosal lesions only (p<0.001). 
Treatments had no impact on EQ-5D-5L index scores at all. Number of comorbidities was 
associated with greater impairment in EQ-5D-5L index scores (p<0.001). The EQ-5D-5L index 
scores were significantly lower among patients with hypertension, musculoskeletal diseases, 
diabetes, thyroid disease and cardiovascular comorbidities (p<0.05). 
 
Discussion 
This is the first study to assess HRQoL in pemphigus patients by using the EQ-5D. Our results 
indicate that the EQ-5D-5L is a feasible and valid instrument for the evaluation of HRQoL for 
pemphigus vulgaris and foliaceus. The EQ-5D-5L index scores correlated at least moderately 
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with all other validated disease severity, pain or HRQoL measures demonstrating a good 
convergent validity of the instrument in pemphigus patients.  
 
The literature is inconsistent with respect to the effect of gender and pemphigus subtype on 
HRQoL. In line with six other investigations,26-28,37-39 we observed no significant difference in 
HRQoL between women and men. Nevertheless, some authors found female patients with 
pemphigus in significantly worse HRQoL.40,41 Regarding pemphigus subtypes, compared to 
PV, our patients with PF reported less problems in all five items of the EQ-5D-5L and had 
slightly better EQ-5D-5L index and EQ VAS scores. Nonetheless, this difference did not reach 
statistical significance. This corroborates findings from three earlier studies examining HRQoL 
in PV and PF patients by using SF-36, DLQI and Skindex-29 questionnaires.39,40,42 We also 
observed that PV patients with mucocutaneous symptoms had the lowest EQ-5D-5L index 
scores, which highlights the importance for additional supportive treatments for mucosal 
symptoms (e.g. topical corticosteroid, gels containing local anaesthetics and intralesional 
corticosteroid injections).8,43-45 
 
Clinical severity, as evaluated by ABSIS, and EQ-5D-5L index scores correlated moderately. 
Interestingly, there was no significant correlation between ABSIS and EQ VAS scores. The 
discrepancy in the convergent validity of EQ-5D-5L index scores and EQ VAS might be 
explained by the difference in how these two instruments capture health status. Not only the 
five dimensions of the EQ-5D descriptive system but any aspects of HRQoL that matter to 
respondents may influence the way that overall health is rated on the EQ-VAS.46 In fact, many 
patients indicating no problems at all in the five dimensions score themselves as less than 100 
in the EQ VAS.47 
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Skin erosions and ulcers in pemphigus may cause debilitating pain. To date, the damaging effect 
of pain on HRQoL in pemphigus have demonstrated in few studies.39,40,48 One study from Iran 
found that the presence of pain did not have a significant negative effect on DLQI scores.27 In 
contrast, our results suggest that pain intensity is one of the most important predictors of 
HRQoL in pemphigus. In clinical settings, thorough pain assessment using well validated tools 
would be essential to develop personalized treatment plans for pemphigus patients.49 Providing 
effective pain relief has a pivotal role in improving patients’ HRQoL. 
 
Patient-perceived impact of psoriasis is well-known and widely studied in the literature.50,51  In 
accordance with previous studies in which the Short Form-36 (SF-36) and the World Health 
Organization Quality of Life-BREF (WHOQOL-BREF) were administered,39,40,52 we found the 
impact of pemphigus very similar to that of psoriasis by the EQ-5D-5L. However, in contrast 
to psoriasis, pemphigus has a relatively high mortality rate, ranging from 5% to 30% after 
diagnosis depending on the length of follow-up.53 Risk of death is approximately 2- to 3-fold 
compared to the general population.2 Considering the high mortality rate, health benefits 
achieved with therapy are expected to be higher in comparison with psoriasis, as effective 
treatments for pemphigus might improve both morbidity and mortality. This will also be 
reflected in cost-effectiveness results of treatments that take into account HRQoL improvement 
as well as life-years saved. 
 
It seems that pemphigus poses a large burden on patients when it comes to usual activities (e.g. 
working/studying, housework, family or leisure activities). The scientific evidence on the 
productivity loss in patients with autoimmune blistering diseases is scarce.54 In Canada, Heelan 
et al. reported a very large burden of autoimmune bullous diseases on ability to work using the 
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Work Productivity and Activity Impairment-Specific Health Problem questionnaire.55 More 
severe disease and larger HRQoL impairment were associated with a greater productivity loss.  
 
Given the rarity of disease, one of the greatest challenges of studying pemphigus is recruiting 
a sufficient number of patients.56 In comparison with published clinical trials and HRQoL 
studies in the field,12,57 the sample size of 109 pemphigus patients may be considered relatively 
large. Further strengths include the multicentre design that allowed to involve the four largest 
autoimmune bullous disease centres in Hungary and the high rate of patients with PF, as 
compared with other studies.25,28,37,39,40,52,58,59 To our knowledge, we were the first to obtain 
health utility values from pemphigus patients. Up to now, only directly elicited utilities were 
available in pemphigus generated with time trade-off method from a general population 
sample.13 Our findings are especially useful considering that in many countries such as the UK, 
France, the Netherlands, Belgium, Hungary and Poland national health technology appraisal 
bodies recommend the EQ-5D for measuring utilities.60-65 
 
The following limitations should be noted. First, patients with severe pemphigus were 
underrepresented in the sample that explains the rather good general health state of patients 
expressed by both the EQ-5D-5L and EQ VAS. Secondly, the English value set has been 
applied in the study, because no national tariff is available for the EQ-5D-5L in Hungary. We 
acknowledge that there are several limitations of transferring value sets and EQ-5D scores 
across different jurisdictions.66 Thirdly, in previous studies, the presence of antibodies against 
desmoglein 1 and 3 (Dsg1 and 3) antigens was associated with disease activity and HRQoL in 
pemphigus.39,42,67-69 Our study was a cross-sectional questionnaire survey; no serum samples 
were collected from patients that could have allowed to measure anti-desmoglein antibody 
levels. In future studies, investigating the correlation between autoantibody levels and EQ-5D 
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index scores is an important research direction. Finally, convergent validity was assessed 
against the ABSIS and DLQI. In validation studies, the Pemphigus Disease Area Index (PDAI) 
performed better in certain psychometric properties (e.g. intra-rater variability, construct 
validity with Dsg 1 and 3 autoantibodies) compared with ABSIS.33 Convergent validity could 
not been tested against autoimmune disease-specific HRQoL tools, such as the Autoimmune 
Bullous Disease Quality of Life (ABQOL)70 and Treatment of Autoimmune Bullous Disease 
Quality of Life (TABQOL),71 which were not available in Hungarian. The development of a 
mapping algorithm between ABQOL or TABQOL and EQ-5D index scores would be 
particularly beneficial in clinical trials where no health utilities are directly measured. 
 
The EQ-5D results in pemphigus are particularly timely. From 2017 rituximab is available as a 
first-line therapy for PV in the US, but in many other countries it is only used as a second- or 
third-line therapy for PV, in part owing to its high costs.10 An increasing number of PV patients 
worldwide is expected to be treated by rituximab in the years to come. The EQ-5D allows to 
measure the health gains associated with high-cost but very effective drugs, such as rituximab. 
No published cost-effectiveness analysis can be found in pemphigus; nevertheless, it is very 
likely that, similarly to psoriasis,72 the EQ-5D will become the major tool to obtain HRQoL 
data in economic evaluations of pemphigus treatments. Thus, the EQ-5D scores reported in the 
present study support resource allocation decisions and might aid to improve patients’ access 
to more effective medicines, in a condition for which only limited treatment options have been 
available, so far.  
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Figure legends 
 
 
Fig. 1 Distribution of responses to the five dimensions of the EQ-5D-5L in pemphigus 
vulgaris and foliaceus compared to psoriasis 
 
 
 
 
Note: Psoriasis data (Hungary, N=238, mean age 47.4±15.2 years, 81% moderate-to-severe psoriasis) - Poór et 
al. 201736 
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Tables 
Table 1 Demographic and clinical characteristics of 109 patients with pemphigus 
 
*Combinations may occur.  
ABSIS = Autoimmune Bullous Skin Disorder Intensity Score 
  
Variables Mean (SD) or N (%) 
Age (years) 57.2 (14.8) 
Gender  
Female 70 (64.2%) 
Male 39 (35.8%) 
Education  
Primary school  22 (20.2%) 
High school 58 (53.2%) 
College/university  29 (26.6%) 
Employment status*  
Employed full-time 41 (37.6%) 
Employed part-time 10 (9.2%) 
Unemployed 6 (5.5%) 
Disability pensioner 15 (13.8%) 
Retired 38 (34.9%) 
Student 1 (0.9%) 
Other 4 (3.7%) 
Disease duration (years) 3.8 (4.9) 
Type of pemphigus  
Pemphigus vulgaris   81 (74.3%) 
Pemphigus foliaceus   27 (24.8%) 
IgA pemphigus 1 (0.9%) 
Severity of pemphigus  
Limited (ABSIS 0-3) 50 (45.9%) 
Moderate (ABSIS 4-16) 33 (30.3%) 
Severe (ABSIS 17-52) 21 (19.3%) 
Extreme (ABSIS 53-206) 5 (4.6%) 
Current treatment  
None 3 (2.8 %) 
Topical therapy (only) 10 (9.2%) 
Systemic therapy* 96 (88.1%) 
Corticosteroid 77 (70.6%) 
Azathioprine 46 (42.2%) 
Cyclophosphamide 11 (10.1%) 
Cyclosporine 1 (0.9%) 
Dapsone 1 (0.9%) 
Intravenous immunoglobulin (IVIg) 1 (0.9%) 
Methotrexate 1 (0.9%) 
Plasmapheresis 1 (0.9%) 
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Table 2 Disease severity and HRQoL scores of pemphigus vulgaris and foliaceus patients 
 
Outcome measures 
 
Total sample Pemphigus vulgaris Pemphigus foliaceus 
p-value 
N Mean (SD) Median (IQR) N Mean (SD) Median (IQR) N Mean (SD) Median (IQR) 
EQ-5D-5L (-0.285 to 1) 108 0.82 (0.21) 0.88 (0.73-1.00) 80 0.81 (0.22) 0.89 (0.71-0.94) 27 0.86 (0.20) 0.94 (0.79-1.00) 0.142 
EQ VAS (0-100) 109 68.0 (22.3) 75 (50-90) 81 67.6 (23.6) 75 (50-90) 27 69.7 (18.6) 75.0 (55.0-82.5) 0.937 
DLQI (0-30) 107 5.4 (6.9) 2 (0-10) 80 5.3 (7.15) 1 (0-10) 26 6.0 (6.0) 5 (0-10) 0.279 
ABSIS (0-206) 109 11.7 (17.3) 4 (0.2-15) 81 13.4 (18.1) 5 (1-21) 27 7.1 (14.5) 3.5 (0-6.5) 0.109 
PGA VAS (0-100) 108 26.9 (27.4) 20 (0-50) 80 28.6 (28.6) 20 (0-50) 27 22.6 (23.5) 10 (0-40) 0.316 
PtGA VAS (0-100) 106 46.0 (35.5) 50  (0-80) 78 47.6 (35.6) 50 (20-80) 27 43.0 (35.3) 50 (0-80) 0.533 
Average pain intensity 
VAS* (0-100) 
106 21.4 (30.6) 0 (0-40) 78 24.0 (31.8) 0 (0-50) 27 14.8 (26.2) 0 (0-20) 0.152 
Worst pain intensity 
VAS* (0-100) 
107 33.6 (37.6) 10 (0-70) 80 38.6 (38.3) 30 (0-80) 26 18.8 (31.8) 0 (0-35) 0.009 
*in the past 3 months  
ABSIS = Autoimmune Bullous Skin Disorder Intensity Score; DLQI = Dermatology Life Quality Index; PGA VAS = Physicians’ Global Assessment of disease severity 
visual analogue scale; PtGA VAS = Patient's Global Assessment of disease severity visual analogue scale; VAS = visual analogue scale 
Bold value indicates a statistically significant difference at p<0.05. 
For EQ-5D-5L and EQ VAS higher scores refer to better health status, for all other measures higher scores represent worse health status. 
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Table 3 Spearman’s correlations between continuous variables 
Variables 
EQ-5D-5L 
(-0.285 to 1) 
EQ VAS DLQI ABSIS PGA VAS PtGA VAS 
Average 
pain 
intensity 
VAS§ 
Worst pain 
intensity 
VAS§ 
Age 
EQ VAS (0-100) 0.607 - - - - - - - - 
DLQI (0-30) -0.619 -0.463 - - - - - - - 
ABSIS (0-206) -0.396 -0.163* 0.543 - - - - - - 
PGA VAS (0-100) -0.460 -0.233 0.627 0.857 - - - - - 
PtGA VAS (0-100) -0.456 -0.147* 0.575 0.574 0.622 - - - - 
Average pain intensity 
VAS§ (0-100) 
-0.593 -0.338 0.649 0.518 0.606 0.643 - - 
- 
Worst pain intensity 
VAS§ (0-100) 
-0.499 -0.298 0.574 0.576 0.612 0.594 0.759 - 
- 
Age (years) -0.252 -0.194 0.060* 0.045* 0.082* 0.060* -0.003* -0.016* - 
Disease duration (years) 0.182* 0.004* -0.190* -0.348 -0.359 -0.285 -0.277 -0.205 0.004* 
*not significant (p≥0.05) 
§ in the past 3 months 
ABSIS = Autoimmune Bullous Skin Disorder Intensity Score; DLQI = Dermatology Life Quality Index; PGA VAS = Physicians’ Global Assessment of disease severity 
visual analogue scale; PtGA VAS = Patient's Global Assessment of disease severity visual analogue scale; VAS = visual analogue scale 
For EQ-5D-5L and EQ VAS higher scores refer to better health status, for all other measures higher scores represent worse health status. 
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Table 4 EQ-5D-5L index scores in subgroups of patients 
 
Variables N Mean (SD) Median (IQR) p-value§ 
Gender     
Female 69 0.82 (0.21) 0.88 (0.71-1.00) 
0.454 
Male 39 0.83 (0.22) 0.92 (0.75-1.00) 
Severity of pemphigus     
Limited (ABSIS 0-3) 49 0.88 (0.18) 0.94 (0.83-1.00) 
0.001 
Moderate (ABSIS 4-16) 33 0.82 (0.21) 0.88 (0.73-0.94) 
Severe (ABSIS 17-52) 21 0.72 (0.23) 0.77 (0.64-0.92) 
Extreme (ABSIS 53-206) 5 0.67 (0.24) 0.70 (0.45-0.87) 
Pemphigus vulgaris subgroup*     
No symptoms 27 0.90 (0.15) 0.94 (0.88-1.00) 
0.001 
Only cutaneous symptoms 25 0.80 (0.22) 0.88 (0.69-0.94) 
Only mucosal symptoms 11 0.79 (0.23) 0.83 (0.69-0.97) 
Mucocutaneous symptoms 15 0.68 (0.21) 0.73 (0.62-0.77) 
Current treatment     
None 3 0.88 (0.16) 0.94 (0.81-0.97) 
0.915 Topical therapy 10 0.86 (0.12) 0.88 (0.77-0.94) 
Systemic therapy 95 0.82 (0.22) 0.88 (0.732-1.00) 
Number of comorbidities     
0 21 0.89 (0.17) 0.94 (0.92-1.00) 
<0.001 
1 26 0.90 (0.15) 0.97 (0.80-1.00) 
2 26 0.81 (0.22) 0.88 (0.68-1.00) 
3 18 0.83 (0.12) 0.85 (0.73-0.92) 
4≤ 17 0.63 (0.29) 0.66 (0.49-0.79) 
Comorbidities     
Hypertension 53 0.80 (0.22) 0.85 (0.71-0.94) 0.048 
Musculoskeletal diseases 34 0.72 (0.25) 0.77 (0.64-0.89) <0.001 
Diabetes 19 0.71 (0.27) 0.79 (0.64-0.88) 0.013 
GERD, gastritis, peptic ulcer disease 13  0.76 (0.29) 0.87 (0.62-1.00) 0.639 
Thyroid disease 12 0.75 (0.14) 0.68 (0.64-0.91) 0.019 
COPD, asthma, allergy 11 0.72 (0.30) 0.79 (0.64-0.94) 0.201 
Cardiovascular diseases (excl. hypertension) 6 0.67 (0.21) 0.73 (0.44-0.86) 0.033 
Bold values indicate a statistically significant difference at p<0.05. 
GERD = gastroesophageal reflux disease; COPD = chronic obstructive pulmonary disease 
* Missing responses n=2 
§ Mann-Whitney U or Kruskal-Wallis H test, where p<0.05 was considered statistically significant. 
 
 
 
 
 
